Percutaneous Closure of Postinfarction Ventricular Septal Defect, an early alternative to surgery.

Original title: Percutaneous Closure of Postinfarction Ventricular Septal Defect: In-Hospital Outcomes and Long-Term Follow-Up of UK Experience. Reference: Circulation. 2014 Jun 10;129(23):2395-402.

As a mechanical post AMI complication, interventricular communication carries a grim prognosis. Surgery has achieved reasonable outcomes but only for those patients who survive the acute phase of healing. Percutaneous closure is a viable early alternative. 

Between 1997 and 2012 percutaneous closure of postinfarction ventricular septal defect was attempted in 53 patients at 11 UK centers. 66% of MI were anterior and 34% inferior. 

Time from MI to closure procedure was 13 days (5-54 range) and devices were successfully implanted in 89% of the population.

Immediate complications in this high risk population included periprocedural death in 3.8% and emergency cardiac surgery in 7.5% of the population.

Right to left shunt was partially occluded in most of patients (62%), completely occluded in 23% and failed despite device implantation in 15%.

58% of treated patients survived to discharge and were followed up to 395 days. During this period. four additional patients died (7.5%).

Factors more strongly associated to postinfarction mortality included age (HR 1.04; p=0.039), female sex (HR=2.33; p=0.043), NYHA functional class IV (HR=4.42; p=0.002), cardiogenic shock (HR=3.75; p=0.003), need for inotropes (HR=4.18; p=0.005) and the absence of revascularization for presenting MI (HR=3.28; p=0.009).

Prior surgical closure and immediate post implantation shunt reduction were associated with better survival.

Conclusion

Percutaneous closure is a reasonable alternative to treat post infarction percutaneous ventricular septal defect. Although mortality was high, patients who survived to discharge had a good long term prognosis. 

Editorial Comment

This option should be considered especially for those patients that develop cardiogenic shock as a symptom of ventricular septal defect, since surgery at the acute phase is difficult due to the friable nature of septal tissue and waiting, in this context, is hardly a viable option.

SOLACI.ORG

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...